BBT-369 is under clinical development by 2Seventy Bio and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BBT-369’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBT-369 is under development for the treatment of relapsed and/or refractory B cell Non-Hodgkin's lymphoma including diffuse large B cell lymphoma (DLBCL), primary mediastinal (Thymic) large B cell lymphoma (PMBCL), high-grade B cell lymphoma (HGBCL), follicular Lymphoma (FL) and DLBCL transformed from FL.. The drug candidate comprises of autologous T- cells genetically modified to express chimeric antigen receptor (CAR). It is developed using MegaTAL gene-editing technology. It acts by targeting CD79a and CD20.
2Seventy Bio overview
2Seventy Bio is focused on discovering and developing new therapies for cancer treatment. 2Seventy Bio is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BBT-369’s drug-specific PTSR and LoA scores, buy the report here.